About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

Brocade Study

Paid Promotion

Brocade StudyMen and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation may qualify for the Brocade Study. The purpose of this medical research study is to determine the safety and effectiveness of the investigational PARP inhibitor, Veliparib in combination with chemotherapy in patients with advanced hereditary breast cancer. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive investigational medication or placebo, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available. To see if you may qualify, call 1.855.5ONCOLOGY (1.855.566.2656) or visit BrocadeStudy.com.

 


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org